OncLive SOSS

The Evolving Treatment Landscape in Light Chain Amyloidosis with Cardiac Involvement - Episode 5

Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

January 8, 2024

Jeffrey Zonder, MD, Shaji Kumar, MD

Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: AL Amyloidosis: Background, Patient Profile, and Staging

EP. 2: Navigating the Differential Diagnosis of AL Amyloidosis

EP. 3: Treatment Approaches in AL Amyloidosis

EP. 4: Limitations of Available Treatment Options for Patients with Cardiac Involvement

EP. 5: Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

EP. 6: Birtamimab Safety Profile in the VITAL Study

EP. 7: Adverse Event Management in AL Amyloidosis

EP. 8: Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

EP. 9: Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

EP. 10: Clinical Pearls and Future Directions in AL Amyloidosis

x